Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Letter in Reply titled “Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease—Reply,”1 published December 2, 2019, there were language errors in 2 sentences that altered meaning. The correct sentences should have read: “We agree that negative results from previous trials that included all types of patients with MCI may not be generalizable to the subset of patients with MCI who have positive results on amyloid PET.” “Even in appropriate patients with AD dementia for whom randomized clinical trials show evidence of positive treatment effects, these medications have modest benefit and may result in nontrivial harm.” This article was corrected online.
Language Errors in Text. JAMA Intern Med. 2020;180(2):338. doi:10.1001/jamainternmed.2019.6864
Coronavirus Resource Center